Literature DB >> 8581072

Glucose metabolism in obese subjects: lessons from OGTT, IVGTT and clamp studies.

A J Scheen1, N Paquot, M R Letiexhe, G Paolisso, M J Castillo, P J Lefèbvre.   

Abstract

Impaired glucose tolerance and overt diabetes are more frequent in presence than in absence of obesity. In obese subjects, glucose tolerance can be maintained within the normal range by compensating for insulin resistance by peripheral hyperinsulinism, the latter resulting from both increased insulin secretion and reduced insulin clearance. Impaired glucose tolerance is observed when insulin resistance is associated to impaired first-phase insulin response, which results in a significant increase in plasma glucose levels and a late insulin hyperresponsiveness. Both hyperinsulinaemia and hyperglycaemia are then able to overcome peripheral insulin resistance and impaired glucose disposal. When a more marked defect in insulin secretion is present, hyperglycaemia progresses, probably due to an additional participation of impaired suppression of hepatic glucose output. Overt diabetes then occurs with persistent post-absorptive hyperglycaemia. All these abnormalities can be reversed after a marked weight loss and recovery of ideal body weight, arguing for acquired rather than inherited metabolic defects in presence of morbid obesity. If a sufficient weight reduction can not be obtained, pharmacological approaches may be considered to improve insulin resistance of obese subjects, especially those with impaired glucose tolerance or overt diabetes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8581072

Source DB:  PubMed          Journal:  Int J Obes Relat Metab Disord


  3 in total

1.  Plasma leptin levels, insulin secretion, clearance and action on glucose metabolism in anorexia nervosa.

Authors:  M R Letiexhe; A J Scheen; P J Lefèbvre
Journal:  Eat Weight Disord       Date:  1997-06       Impact factor: 4.652

2.  Insulin clearance: confirmation as a highly heritable trait, and genome-wide linkage analysis.

Authors:  X Guo; J Cui; M R Jones; T Haritunians; A H Xiang; Y-D I Chen; K D Taylor; T A Buchanan; R C Davis; W A Hsueh; L J Raffel; J I Rotter; M O Goodarzi
Journal:  Diabetologia       Date:  2012-05-16       Impact factor: 10.122

3.  Therapeutic silencing of fat-specific protein 27 improves glycemic control in mouse models of obesity and insulin resistance.

Authors:  Cédric Langhi; Noemí Arias; Ananthi Rajamoorthi; Jeannine Basta; Richard G Lee; Ángel Baldán
Journal:  J Lipid Res       Date:  2016-11-24       Impact factor: 5.922

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.